37.16
price up icon0.69%   0.255
after-market アフターアワーズ: 37.17 0.005 +0.01%
loading
前日終値:
$36.91
開ける:
$37.2
24時間の取引高:
930.19K
Relative Volume:
1.01
時価総額:
$3.22B
収益:
$522.75M
当期純損益:
$-558.99M
株価収益率:
-5.7442
EPS:
-6.47
ネットキャッシュフロー:
$-439.53M
1週間 パフォーマンス:
+9.21%
1か月 パフォーマンス:
+6.00%
6か月 パフォーマンス:
-24.74%
1年 パフォーマンス:
-11.02%
1日の値動き範囲:
Value
$36.50
$37.48
1週間の範囲:
Value
$34.10
$37.48
52週間の値動き範囲:
Value
$29.59
$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name
名前
Ultragenyx Pharmaceutical Inc
Name
セクター
Healthcare (1170)
Name
電話
415-483-8800
Name
住所
60 LEVERONI COURT, NOVATO, CA
Name
職員
1,294
Name
Twitter
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
RARE's Discussions on Twitter

RARE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RARE
Ultragenyx Pharmaceutical Inc
37.16 3.22B 522.75M -558.99M -439.53M -6.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-28 開始されました William Blair Outperform
2024-06-06 アップグレード Goldman Neutral → Buy
2024-04-22 開始されました RBC Capital Mkts Outperform
2023-12-08 開始されました Wells Fargo Overweight
2023-06-14 再開されました Credit Suisse Outperform
2023-06-06 アップグレード Evercore ISI In-line → Outperform
2023-04-26 開始されました Cantor Fitzgerald Overweight
2023-01-18 再開されました Canaccord Genuity Buy
2022-12-30 再開されました H.C. Wainwright Buy
2022-11-03 アップグレード Robert W. Baird Neutral → Outperform
2022-10-13 アップグレード Guggenheim Neutral → Buy
2022-08-01 ダウングレード Evercore ISI Outperform → In-line
2022-03-16 アップグレード Credit Suisse Neutral → Outperform
2022-02-11 アップグレード JP Morgan Neutral → Overweight
2021-09-30 開始されました H.C. Wainwright Buy
2021-08-19 開始されました UBS Sell
2021-07-15 開始されました Guggenheim Neutral
2021-06-29 アップグレード BofA Securities Neutral → Buy
2021-06-04 再開されました Robert W. Baird Neutral
2021-05-06 アップグレード Citigroup Neutral → Buy
2021-05-06 アップグレード Evercore ISI In-line → Outperform
2021-04-26 再開されました Credit Suisse Neutral
2021-03-02 再開されました Stifel Buy
2021-02-12 ダウングレード JP Morgan Overweight → Neutral
2020-12-07 ダウングレード Wedbush Outperform → Neutral
2020-11-24 再開されました Evercore ISI In-line
2020-11-12 ダウングレード BofA Securities Buy → Neutral
2019-08-02 再開されました Wedbush Outperform
2019-03-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2019-02-22 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-11-08 アップグレード Citigroup Sell → Neutral
2018-09-10 開始されました Morgan Stanley Equal-Weight
2018-06-21 ダウングレード Credit Suisse Outperform → Neutral
2018-05-11 アップグレード Barclays Equal Weight → Overweight
2018-05-10 開始されました Goldman Neutral
2018-04-18 アップグレード SunTrust Hold → Buy
2018-03-22 再開されました Piper Jaffray Overweight
2018-02-21 繰り返されました Stifel Buy
2018-01-22 アップグレード Evercore ISI In-line → Outperform
2018-01-18 開始されました Credit Suisse Outperform
2017-12-05 繰り返されました Barclays Equal Weight
2017-12-04 アップグレード Jefferies Hold → Buy
2017-09-14 アップグレード Wedbush Neutral → Outperform
すべてを表示

Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース

pulisher
Jun 05, 2025

Ultragenyx reports 28% rise in Q1 revenue from year ago - The Press Democrat

Jun 05, 2025
pulisher
Jun 05, 2025

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

Mucopolysaccharidosis III Pipeline 2025: Groundbreaking - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

How the (RARE) price action is used to our Advantage - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 03, 2025

Ultragenyx to Participate at Goldman Sachs 46th Annual Global He - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference | RARE Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Ultragenyx CEO Reveals Latest Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan

Jun 03, 2025
pulisher
May 29, 2025

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline - openPR.com

May 29, 2025
pulisher
May 29, 2025

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (BMV:RARE) with Outperform Recommendation - Nasdaq

May 29, 2025
pulisher
May 29, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at William Blair - Defense World

May 29, 2025
pulisher
May 28, 2025

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (LSE:0LIF) with Outperform Recommendation - Nasdaq

May 28, 2025
pulisher
May 28, 2025

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (RARE) with Outperform Recommendation - MSN

May 28, 2025
pulisher
May 28, 2025

William Blair sets Ultragenyx stock at Outperform with $65 target By Investing.com - Investing.com Australia

May 28, 2025
pulisher
May 28, 2025

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical - Benzinga

May 28, 2025
pulisher
May 28, 2025

Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga

May 28, 2025
pulisher
May 28, 2025

Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Out - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Outperform' Rating | RARE Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

William Blair Initiates Ultragenyx Pharmaceutical at Outperform - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

William Blair sets Ultragenyx stock at Outperform with $65 target - Investing.com

May 28, 2025
pulisher
May 28, 2025

Ultragenyx (RARE) Gains Outperform Rating with $65 Target | RARE Stock News - GuruFocus

May 28, 2025
pulisher
May 26, 2025

Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com

May 26, 2025
pulisher
May 25, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Nigeria

May 25, 2025
pulisher
May 25, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com

May 25, 2025
pulisher
May 21, 2025

CDKL5 Deficiency Disorder Market Expected to Experience Major - openPR.com

May 21, 2025
pulisher
May 21, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 21, 2025
pulisher
May 20, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 56 - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Ultragenyx Grants $4.5M in Stock Awards: 20 New Hires Receive Retention Packages - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Ultragenyx Pharmaceutical Approves Key Proposals at Annual Meeting - MSN

May 20, 2025
pulisher
May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Inno - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report | RARE Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

(RARE) Technical Pivots with Risk Controls - news.stocktradersdaily.com

May 14, 2025
pulisher
May 13, 2025

Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com

May 13, 2025
pulisher
May 12, 2025

Glycogen Storage Disease Treatment Market Size in 7MM - openPR.com

May 12, 2025
pulisher
May 09, 2025

RARE: Morgan Stanley Raises Price Target for Ultragenyx Pharmace - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com

May 09, 2025
pulisher
May 09, 2025

RARE: Morgan Stanley Raises Price Target for Ultragenyx Pharmaceutical | RARE Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st

May 09, 2025
pulisher
May 09, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y - MSN

May 09, 2025
pulisher
May 09, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025
pulisher
May 08, 2025

Ultragenyx to Participate at Bank of America's 2025 Healthcare C - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Ultragenyx price target lowered to $100 from $140 at Truist - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being - simplywall.st

May 08, 2025
pulisher
May 08, 2025

Truist Financial Remains a Buy on Ultragenyx Pharmaceutical (RARE) - The Globe and Mail

May 08, 2025
pulisher
May 08, 2025

Ultragenyx Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Decoding Ultragenyx Pharmaceutical Inc (RARE): A Strategic SWOT Insight - GuruFocus

May 08, 2025
pulisher
May 07, 2025

Ultragenyx Reports Strong Growth Amid Challenges - TipRanks

May 07, 2025

Ultragenyx Pharmaceutical Inc (RARE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Ultragenyx Pharmaceutical Inc (RARE) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Crombez Eric
EVP and Chief Medical Officer
Apr 21 '25
Sale
35.11
242
8,497
71,680
Horn Howard
Chief Financial Officer
Mar 06 '25
Sale
40.40
1,785
72,114
106,169
Kassberg Thomas Richard
CBO & EVP
Mar 03 '25
Sale
42.10
6,028
253,779
265,238
Parschauer Karah Herdman
EVP and Chief Legal Officer
Mar 03 '25
Sale
42.10
12,846
540,817
75,287
Crombez Eric
EVP and Chief Medical Officer
Mar 03 '25
Sale
42.10
8,945
376,584
71,922
Pinion John Richard
See Remarks
Mar 03 '25
Sale
42.10
14,439
607,882
107,766
KAKKIS EMIL D
President & CEO
Mar 03 '25
Sale
42.10
73,434
3,091,571
641,731
KAKKIS EMIL D
President & CEO
Feb 28 '25
Sale
42.48
25,000
1,062,000
2,158,985
Harris Erik
EVP & Chief Commercial Officer
Mar 03 '25
Sale
42.10
15,103
635,836
87,855
Huizenga Theodore Alan
SVP, Chief Accounting Officer
Mar 03 '25
Sale
42.10
967
40,711
50,265
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
大文字化:     |  ボリューム (24 時間):